| Literature DB >> 28086962 |
Henna Jaurila1,2, Vesa Koivukangas3, Marjo Koskela3, Fiia Gäddnäs3, Sirpa Salo4, Johanna Korvala5, Maija Risteli5, Toni Karhu6, Karl-Heinz Herzig6,7, Tuula Salo5,8, Tero I Ala-Kokko3.
Abstract
BACKGROUND: Sepsis delays wound re-epithelialization. In this study we explored the effect of human sepsis sera as well as the effects of cytokines, growth factors and exosomes of sepsis sera treated normal fibroblasts (NF) on keratinocyte migration and proliferation in vitro.Entities:
Keywords: EGF; Exosome; HaCaT; Human serum; In vitro; Migration; Sepsis; TNF-α
Mesh:
Substances:
Year: 2017 PMID: 28086962 PMCID: PMC5237124 DOI: 10.1186/s12967-016-1110-7
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Summary demographics of the 44 study patients with severe sepsis
| Severe sepsis (n = 44) | |
|---|---|
| Male sex, n (%) | 29 (66%) |
| Age, years | 63 (56–71) |
| Surgical admission, n (%) | 25 (57%) |
| Septic shock, n (%) | 40 (91%) |
| APACHE II score on admission, points | 26 (22–31) |
| SOFA score on admission, points | 8 (6–12) |
| Length of stay in the ICU, days | 7 (4–12) |
| 30-day mortality, n (%) | 11 (25%) |
Variables are presented as frequencies with percentages or as medians with 25th to 75th percentiles
Apache II acute physiology and chronic health evaluation II score
Sofa sequential organ failure assessment
Fig. 1Keratinocyte (HaCaT) proliferation after exposure to healthy and sepsis sera (BrdU assay). Statistically significant differences in mean absorbance values between cells treated with sepsis and healthy sera are marked with asterisks (*P = 0.005, **P = 0.001, ***P = 0.002)
Fig. 2Keratinocyte viability after exposure to healthy and sepsis sera (MTT assay). Statistically significant differences in mean absorbance values between cells treated with sepsis sera and cells treated with healthy sera are marked with asterisks (*P = 0.01, **P < 0.001)
Fig. 3Keratinocyte migration after exposure to healthy and sepsis sera (horizontal wound-healing assay). a An example of the wound surface area calculation from the microscopy images of cell migration in wounds after 0, 24 and 48 h exposure to healthy or sepsis sera. White dotted lines mark the open wound area. The open surface area was measured using ImageJ. b Closure of open wound areas of keratinocytes at 0, 24 and 48 h (% of 0 h area). The data present means with standard deviations from eight scratch wounds incubated with day 1, 4, and 9 sepsis sera and means with standard deviations from four healthy sera control wounds
Fig. 4Keratinocyte migration in wounded monolayer after exposure to exosomes. Exosomes derived from healthy sera (HS NF-Exo) and sepsis sera (SS NF-Exo) treated normal fibroblasts were used in 20 or 50 µg/ml concentrations. Wound area (%) reduction was followed 48 h and data are presented as means with standard deviations from seven wounds per group
Cytokine levels (pg/ml) in sera from patients with severe sepsis (day four) and healthy sera
| Cytokine | Sepsis sera | Healthy control sera | P value |
|---|---|---|---|
| EGF | 6.5 (14.5) | 115.6 (114.1) | <0.001 |
| TNF-α | 5.7 (4.9) | 0.7 (0.2) | <0.001 |
| IL-6 | 24.8 (20.6) | 3.8 (5.4) | <0.001 |
| VEGF | 177.9 (185.7) | 48.1 (32.2) | 0.018 |
| IL-10 | 30.0 (49.7) | 11.9 (16.3) | 0.040 |
| IL-4 | 5.2 (9.7) | 13.7 (24.9) | 0.352 |
| bFGF | 32.2 (37.7) | 21.9 (13.6) | 0.810 |
Data are expressed as mean values and SD
Fig. 5Keratinocyte migration after exposure to healthy and sepsis sera supplemented with cytokines and EGFR inhibitor. Migration was studied using a horizontal wound-healing assay and the open wound area (%) was measured by ImageJ every 12 h until 48 h. The data present means from four to eight wounds in every group. Graphs show results from control and test serums containing a 5–50 ng/ml TNF-α b 5–50 ng/ml EGF c 1–50 µg/ml EGFR inhibitor (cetuximab)
Serum supplemented with TNF-α/EGF/EGFR inhibitor, open wound surface area (%) of the original at 48 h
| Serum | Cytokine | Amount of cytokine | Number of wounds | Mean % (SD) | P value |
|---|---|---|---|---|---|
| Healthy (control) | − | − | 8 | 61 (15) | |
| Sepsis (control) | − | − | 8 | 75 (20) | |
| Healthy | TNF-α | 5 ng/ml | 8 | 14 (15) | < |
| Sepsis | TNF-α | 5 ng/ml | 7 | 44 (19) |
|
| Healthy | TNF-α | 10 ng/ml | 7 | 13 (15) | < |
| Sepsis | TNF-α | 10 ng/ml | 5 | 30 (20) |
|
| Healthy | TNF-α | 50 ng/ml | 6 | 7 (16) |
|
| Sepsis | TNF-α | 50 ng/ml | 5 | 16 (18) |
|
| Healthy | EGF | 5 ng/ml | 6 | 0 (0) |
|
| Sepsis | EGF | 5 ng/ml | 8 | 2 (5) |
|
| Healthy | EGF | 10 ng/ml | 8 | 9 (17) |
|
| Sepsis | EGF | 10 ng/ml | 6 | 72 (57) | 0.301 |
| Healthy | EGF | 50 ng/ml | 4 | 51 (59) | 0.768 |
| Sepsis | EGF | 50 ng/ml | 6 | 77 (39) | 0.887 |
| Healthy | EGFr inhibitor | 1 µg/ml | 7 | 84 (24) |
|
| Sepsis | EGFr inhibitor | 1 µg/ml | 7 | 96 (7) |
|
| Healthy | EGFr inhibitor | 10 µg/ml | 5 | 95 (11) |
|
| Sepsis | EGFr inhibitor | 10 µg/ml | 6 | 106 (10) |
|
| Healthy | EGFr inhibitor | 50 µg/ml | 7 | 95 (4) |
|
| Sepsis | EGFr inhibitor | 50 µg/ml | 7 | 99 (2) |
|
Healthy serum samples are compared to healthy control serum and sepsis serum samples to sepsis control serum. Significant P values are in italic